594
Participants
Start Date
June 30, 2016
Primary Completion Date
July 27, 2020
Study Completion Date
July 27, 2020
Rebif (Interferon beta-1a)
Rebif will be administered at a dose of 44 mcg, sc, tiw.
Research site, Algiers
Research site, Annaba
Research site, Blida
Research site, Oran
Research site, Sétif
Research site, Tizi Ouzou
Research site, Mendoza
Research site, Rosario
Research site, San Miguel de Tucumán
Research site, Manama
Research site, Sofia
Research site, Al Mansurah
Research site, Alexandria
Research site 1, Cairo
Research site 2, Cairo
Research site 1, Budapest
Research site 2, Budapest
Research site 3, Budapest
Research site, Esztergom
Research site, Isfahan
Research site, Tehran
Research site, Kuwait City
Research site 1, Beirut
Research site 2, Beirut
Research site, Casablanca
Research site, Fés
Research site, Marrakesh
Research site 1, Rabat
Research site 2, Rabat
Research site 3, Rabat
Research site, Gdansk
Research site, Katowice
Research site, Lodz
Research site, Lublin
Research site, Rybnik
Research site, Warsaw
Research site, Dammam
Research site, Jeddah
Research site, Khober
Research site, Riyadh
Research site 2, Seoul
Merck Serono Middle East FZ LLC
INDUSTRY
Merck KGaA, Darmstadt, Germany
INDUSTRY